| Advanced Eyecare Of Minnesota P.a. | |
|
2210 Highway 29 S, Alexandria, MN 56308-3487 | |
| (218) 639-0343 | |
| (218) 824-0020 |
| Full Name | Advanced Eyecare Of Minnesota P.a. |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 2210 Highway 29 S, Alexandria, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316304124 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | MN1980 (Minnesota) | Primary |
| Provider Name | Lamar W Gunnarson |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1336137256 PECOS PAC ID: 6608869680 Enrollment ID: I20040406000477 |
News Archive
OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.
In a new study, young children and their adult caregivers uttered fewer vocalizations, used fewer words and engaged in fewer conversations when in the presence of audible television.
STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today reported results for the third quarter ended October 1, 2010. Revenue for the period grew 6% to $13.2 million reflecting core product (IOLs and ICLs) revenue growth of 10% and a 44% decrease in defocused product revenue as compared to the third quarter of 2009.
Using a set of different monoclonal antibodies, researchers determined different mutations in the SARS-CoV-2 spike protein that leads to resistance. Understanding these resistant mutations is important in developing effective therapeutic strategies.
› Verified 2 days ago
| Provider Name | Jenna K Backowski |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1831502244 PECOS PAC ID: 8820212525 Enrollment ID: I20140620000095 |
News Archive
OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.
In a new study, young children and their adult caregivers uttered fewer vocalizations, used fewer words and engaged in fewer conversations when in the presence of audible television.
STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today reported results for the third quarter ended October 1, 2010. Revenue for the period grew 6% to $13.2 million reflecting core product (IOLs and ICLs) revenue growth of 10% and a 44% decrease in defocused product revenue as compared to the third quarter of 2009.
Using a set of different monoclonal antibodies, researchers determined different mutations in the SARS-CoV-2 spike protein that leads to resistance. Understanding these resistant mutations is important in developing effective therapeutic strategies.
› Verified 2 days ago
| Provider Name | Scott A Minnerath |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1336719475 PECOS PAC ID: 9436552205 Enrollment ID: I20210730002772 |
News Archive
OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.
In a new study, young children and their adult caregivers uttered fewer vocalizations, used fewer words and engaged in fewer conversations when in the presence of audible television.
STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today reported results for the third quarter ended October 1, 2010. Revenue for the period grew 6% to $13.2 million reflecting core product (IOLs and ICLs) revenue growth of 10% and a 44% decrease in defocused product revenue as compared to the third quarter of 2009.
Using a set of different monoclonal antibodies, researchers determined different mutations in the SARS-CoV-2 spike protein that leads to resistance. Understanding these resistant mutations is important in developing effective therapeutic strategies.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Advanced Eyecare Of Minnesota P.a. 203 Hawkins Dr, Brainerd, MN 56401-3916 Ph: () - | Advanced Eyecare Of Minnesota P.a. 2210 Highway 29 S, Alexandria, MN 56308-3487 Ph: (218) 639-0343 |
News Archive
OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.
In a new study, young children and their adult caregivers uttered fewer vocalizations, used fewer words and engaged in fewer conversations when in the presence of audible television.
STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today reported results for the third quarter ended October 1, 2010. Revenue for the period grew 6% to $13.2 million reflecting core product (IOLs and ICLs) revenue growth of 10% and a 44% decrease in defocused product revenue as compared to the third quarter of 2009.
Using a set of different monoclonal antibodies, researchers determined different mutations in the SARS-CoV-2 spike protein that leads to resistance. Understanding these resistant mutations is important in developing effective therapeutic strategies.
› Verified 2 days ago
Gess Eye Clinic P.a. Optometrist Medicare: Medicare Enrolled Practice Location: 109 15th Ave E, Alexandria, MN 56308 Phone: 320-762-5112 Fax: 320-763-3297 | |
Dr. Todd Donovan Olson, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2306 S Broadway St, Alexandria, MN 56308 Phone: 320-763-7782 Fax: 320-763-0504 | |
Dr Eleanor S Haney Pc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 4611 Highway 29 S, Alexandria, MN 56308 Phone: 320-762-4044 Fax: 320-762-4046 | |
Eye Associates Of Alexandria Optometrist Medicare: Medicare Enrolled Practice Location: 120 12th Ave E, Alexandria, MN 56308 Phone: 320-763-4321 Fax: 320-763-6921 | |
Runestone Eye Care Optometrist Medicare: Medicare Enrolled Practice Location: 3015 Highway 29 S, Suite 4155, Alexandria, MN 56308 Phone: 320-759-1130 | |
Dr. Jeremy R Anderson, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 120 12th Ave E, Alexandria, MN 56308 Phone: 320-763-4321 Fax: 320-763-6921 | |
Dr. Jenna Rose Kryder, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 1610 Broadway St, Alexandria, MN 56308 Phone: 320-763-4321 Fax: 320-763-6921 |